Trial Profile
A phase II prospective, multicenter, randomized controlled trial of maintenance therapy of apatinib combined with capecitabine for recurrent/metastatic and persistent cervical cancer after chemoradiotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Rivoceranib (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- 26 Jul 2018 New trial record